Summit Therapeutics Inc. announced the appointment of Jeff Huber to its Board of Directors. Huber brings a wealth of experience in healthcare and technology, having served in leadership roles at companies like GRAIL, Alphabet Inc., and Google. He is currently the Co-Founder and General Partner of Triatomic Capital Private LP. His addition to the Summit team is expected to enhance their efforts to redefine cancer treatment with the innovative antibody candidate ivonescimab. Huber expressed his excitement to work with Summit in their mission to improve patients’ quality of life and life span.
Ivonescimab, also known as SMT112, is a groundbreaking investigational bispecific antibody developed by Akeso Inc. The molecule combines PD-1 blockade with VEGF blockade to target tumor tissue more effectively than healthy tissue. Ivonescimab has shown promising results in clinical trials for non-small cell lung cancer, with plans for further development in other cancer types.
Summit Therapeutics Inc. is a biopharmaceutical company dedicated to developing innovative therapies to address unmet medical needs. The company’s mission is centered around improving patient outcomes and quality of life. With headquarters in Miami, Florida, Summit is listed on the Nasdaq Global Market under the ticker symbol “SMMT.”
Forward-looking statements from Summit reflect the company’s expectations and plans for the future, including the development of their product candidates and potential partnerships. Factors such as market conditions, regulatory approvals, and clinical trial results can impact the company’s success. Summit remains committed to advancing the development and commercialization of ivonescimab to benefit patients worldwide.
For more information about Summit Therapeutics Inc. and their work with ivonescimab, visit their website or contact their Investor Relations team. Join the conversation on social media by following @SMMT_TX.
Article Source
https://finance.yahoo.com/news/summit-therapeutics-appoints-jeff-huber-201500707.html
